Lapatinib

Generic Name: Lapatinib

Brand Names: Tykerb, Tyverb

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₂₆ClFN_₄O_₄S

CAS Number: 231277-92-2

Unique Ingredient Identifier: 0VUA21238F

Background: Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2...

Indication: Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.

Associated Conditions: Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer

Associated Therapies: -

Clinical Trials

Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: lapatinib
Drug: Capecitabine

First Posted Date: 2007-12-17

Last Posted Date: 2019-12-18

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 29

Registration Number: NCT00574171

Locations: 🇺🇸
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Phase 2

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: lapatinib
Drug: Pazopanib

First Posted Date: 2007-11-14

Last Posted Date: 2013-02-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 163

Registration Number: NCT00558103

Locations: 🇬🇧
GSK Investigational Site, Sutton, United Kingdom

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Phase 3

Completed

Conditions: Neoplasms, Breast

Interventions: Biological: Trastuzumab
Drug: Lapatinib
Drug: Paclitaxel

First Posted Date: 2007-11-04

Last Posted Date: 2021-09-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 455

Registration Number: NCT00553358

Locations: 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom

Lapatinib and Trastuzumab With or Without Endocrine Therapy

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Lapatinib
Drug: Trastuzumab
Drug: Endocrine

First Posted Date: 2007-10-23

Last Posted Date: 2019-11-07

Lead Sponsor: Baylor Breast Care Center

Target Recruit Count: 65

Registration Number: NCT00548184

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bunting-Blaustein Cancer Research, Baltimore, Maryland, United States
🇺🇸
UAB Cancer Center, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

and more 3 locations

Bevacizumab in Multiple Phase I Combinations

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Bevacizumab
Drug: Sunitinib
Drug: Sorafenib
Drug: Erlotinib
Drug: Trastuzumab
Drug: Cetuximab
Drug: Lapatinib

First Posted Date: 2007-10-15

Last Posted Date: 2020-06-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 343

Registration Number: NCT00543504

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer

Phase 1

Completed

Conditions: Neoplasms, Colorectal

Interventions: Drug: lapatinib
Drug: oxaliplatin
Drug: capecitabine

First Posted Date: 2007-09-28

Last Posted Date: 2017-12-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT00536809

Locations: 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States

A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase

Phase 1

Completed

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: Lapatinib
Drug: Pemetrexed

First Posted Date: 2007-09-12

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT00528281

Locations: 🇬🇧
GSK Investigational Site, Newcastle upon Tyne, United Kingdom

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

Phase 2

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: Trastuzumab
Drug: Paclitaxel
Drug: FEC75
Drug: Lapatinib

First Posted Date: 2007-09-03

Last Posted Date: 2016-11-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 100

Registration Number: NCT00524303

Locations: 🇺🇸
GSK Investigational Site, Yakima, Washington, United States

Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

Phase 1

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: pazopanib
Drug: Lapatinib

First Posted Date: 2007-08-15

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT00516672

Locations: 🇯🇵
GSK Investigational Site, Saitama, Japan

Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Lapatinib
Drug: vinorelbine

First Posted Date: 2007-08-08

Last Posted Date: 2014-01-14

Lead Sponsor: UNICANCER

Target Recruit Count: 33

Registration Number: NCT00513058

Locations: 🇫🇷
Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France
🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷
Institut Curie Hopital, Paris, France

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy